dimethyl ({2[(2-methylpropyl)amino]ethyl})amine | 926205-56-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: dimethyl ({2[(2-methylpropyl)amino]ethyl})amine
• 英文别名: [2-(Dimethylamino)ethyl](2-methylpropyl)amine；N',N'-dimethyl-N-(2-methylpropyl)ethane-1,2-diamine
• CAS: 926205-56-3
• 化学式: C₈H₂₀N₂
• mdl: MFCD09045199
• 分子量: 144.26
• InChiKey: GOZSCJXMGZBZIF-UHFFFAOYSA-N

物化性质

• 沸点：
  170.0±8.0 °C(Predicted)
• 密度：
  0.814±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3'SR,4'aRS,8'aRS)-1'-propyl-octahydro-1'H-spiro[1,3-dioxolane-2,6'-quinoline]-3'-carboxylic acid 、 dimethyl ({2[(2-methylpropyl)amino]ethyl})amine 在 叠氮磷酸二苯酯 、 N,N-二异丙基乙胺 作用下， 以 甲苯 为溶剂， 反应 6.0h， 以404 mg的产率得到3-[(3'SR,4'aRS,8'aRS)-1'-propyl-octahydro-1'H-spiro[1,3-dioxolane-2,6'-quinoline]-3'-yl]-3-[2-(dimethylamino)ethyl]-1-(2-methylpropyl)urea
  参考文献：
  名称：

  新規なドパミンＤ２受容体アゴニスト

  摘要：

  提供具有多巴胺D2受体激动剂作用，并减轻5-HT2B受体刺激作用的药物组合物。含有化合物或其药理学上可接受的盐的药物组合物，其由通式（I）表示。【R1为C1-6烷基等；R2为氢或C1-6烷基；R3和R4分别独立为H，C1-6烷基，R10R11N-C1-6烷基，芳基烷基等；R5和R6分别独立为H或C1-7酰基；R7为H，卤素等】。【选择图】无。

  公开号：

  JP2016011291A

文献信息

• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• [EN] PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS À BASE DE KÉTAMINE, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：XW LAB INC

  公开号：WO2019137381A1

  公开（公告）日：2019-07-18

  Provided are prodrugs of (S) -or (R) -ketamine, including isotopically labeled ketamine,composition and uses thereof. Compounds having formula (Ia) or (Ib) as the prodrugs of (S) -or (R) -ketamine, including isotopically labeled ketamine, and pharmaceutical compositions comprising the compounds provided herein are used for treating or preventing a CNS disease.More particularly, the related diseases include depression and pain. (Ia) (Ib)

  提供了（S）-或（R）-氯胺酮的前药，包括同位素标记的氯胺酮，其组成和用途。具有化学式（Ia）或（Ib）的化合物作为（S）-或（R）-氯胺酮的前药，包括同位素标记的氯胺酮，以及包含本文提供的化合物的药物组合物用于治疗或预防中枢神经系统疾病。更具体地，相关疾病包括抑郁症和疼痛。（Ia）（Ib）
• (AMIDE AMINO ALKANE) METAL COMPOUND, METHOD OF MANUFACTURING METAL-CONTAINING THIN FILM USING SAID METAL COMPOUND
  申请人：Fujimura Osamu

  公开号：US20130273250A1

  公开（公告）日：2013-10-17

  The present invention relates to an (amide amino alkane) metal compound represented by the formula (1): wherein M represents a metal atom; R 1 represents a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms; R 2 and R 3 may be the same as, or different from each other, and each independently represents a linear or branched alkyl group having 1 to 3 carbon atoms, or R 2 and R 3 may form a substituted or unsubstituted 5- or 6-membered ring together with the nitrogen atom to which they are bound; Z represents a linear or branched alkylene group having 1 to 10 carbon atoms (a part of which may optionally form a ring); and n represents a number of the ligands, which is equal to the valence of the metal (M), and represents an integer of from 1 to 3; with the proviso that the metal compounds in which M is Li (Lithium), Be (Beryllium), Ge (Germanium) or Nd (Neodymium) are excluded; the metal compounds in which M is Mg (Magnesium) and R 1 is methyl group are excluded; the metal compounds in which M is Zn (Zinc) and R 1 is methyl group are excluded; the metal compounds in which M is Bi (Bismuth) and R 1 is t-butyl group are excluded; and in cases where n is two or greater, two or more ligands may be the same as, or different from each other; and a method of producing a metal-containing thin film using the metal compound.

  本发明涉及一种由式（1）表示的（酰胺氨基烷）金属化合物：其中，M代表金属原子；R1代表具有1至6个碳原子的线性、支链或环烷基；R2和R3可以相同，也可以不同，每个独立地表示具有1至3个碳原子的线性或支链烷基，或者R2和R3可以与它们所连接的氮原子一起形成取代或未取代的5-或6-成员环；Z代表具有1至10个碳原子的线性或支链亚烷基（其中的一部分可以选择地形成环）；n代表配体的数量，其等于金属（M）的价，表示为1至3的整数。但是，M为锂（Li）、铍（Be）、锗（Ge）或钕（Nd）的金属化合物被排除；M为镁（Mg）且R1为甲基基团的金属化合物被排除；M为锌（Zn）且R1为甲基基团的金属化合物被排除；M为铋（Bi）且R1为叔丁基基团的金属化合物被排除；在n为2或更大的情况下，两个或更多的配体可以相同或不同；以及使用该金属化合物制备含金属薄膜的方法。
• B-RAF KINASE INHIBITORS
  申请人：Steurer Steffen

  公开号：US20130190286A1

  公开（公告）日：2013-07-25

  The present invention encompasses compounds of general formula (1) where in the groups R 0 to R 3 and L are defined as in claim 1 , which are suitable for the 5 treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

  本发明涵盖了通式（1）的化合物，其中R0到R3和L的定义如权利要求1所述，适用于治疗由过度或异常细胞增殖所特征的疾病，包含这种化合物的制药制剂以及它们作为药物的使用。
• PYRIDYLTRIAZOLES
  申请人：Ettmayer Peter

  公开号：US20130225562A1

  公开（公告）日：2013-08-29

  The present invention encompasses compounds of general formula (1) wherein the groups R 0 to R 3 and L are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.

  本发明涵盖通式（1）的化合物，其中R0至R3和L基团的定义如权利要求1所述，适用于治疗由过度或异常细胞增殖特征的疾病，包含这种化合物的制药制剂以及它们作为药物的用途。